C-MET NSCLC Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential

DelveInsight's "C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the C-MET Non-Small Cell Lung Cancer pipeline landscape. It covers the C-MET+ NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the C-MET+ NSCLC therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the c-MET-NSCLC Treatment Landscape. Click here to read more @ c-MET-NSCLC Pipeline Outlook [https://www.delveinsight.com/sample-request/c-met-non-small-cell-lung-cancer-cmetnsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the c-MET-NSCLC Pipeline Report

* On 29 September 2025, AbbVie announced a Phase 2 study of Three Telisotuzumab Vedotin Regimens in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer.
* On 14 September 2025, EMD Serono Research & Development Institute Inc . organized a study looked at how effective the study drug (tepotinib) was at stopping the growth and spread of lung cancer. This study also measures a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the study drug affects your quality of life. The study also has an optional pharmacogenetic research part. Pharmacogenetic research is an important way to try to understand the role of genetics in human disease and how genes impact the effectiveness of drugs, because differences in genes can change the way a person responds to a particular drug.
* DelveInsight's c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for c-MET-NSCLC treatment.
* The leading c-MET-NSCLC Companies such as AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis , and others.
* Promising C-MET NSCLC Therapies such as Glumetinib, Tepotinib, INC280, APL-101 Oral Capsules, MCLA-129, Osimertinib , and others.

Stay informed about the cutting-edge advancements in c-MET NSCLC treatments. Download for updates and be a part of the revolution in cancer care @ c-MET NSCLC Clinical Trials Assessment [https://www.delveinsight.com/sample-request/c-met-non-small-cell-lung-cancer-cmetnsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

c-MET NSCLC Emerging Drugs Profile

* JNJ-61186372: Janssen Research & Development, LLC

JNJ-6372 is an EGFR-MET bispecific antibody with immune cell-directing activity that targets activating and resistant EGFR and MET mutations and amplifications. The production and development of the antibody followed Janssen's licensing agreement with Genmab for use of its DuoBody technology platform. According to the company, JNJ-6372 is a novel bispecific antibody that has the potential to benefit patients with Exon 20 mutation insertions who often do not respond to currently available oral EGFR-targeted or immune checkpoint inhibitor therapies.

* PLB1001 - Beijing Pearl Biotechnology Limited Liability Company

PLB1001 is an orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) with potential antineoplastic activity. Upon administration, PLB1001 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.

The C-MET NSCLC Pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of C-MET NSCLC with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for C-MET NSCLC Treatment.
* C-MET NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* C-MET NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the C-MET NSCLC market.

Learn more about c-MET NSCLC Drugs opportunities in our groundbreaking c-MET NSCLC Research and development projects @ c-MET NSCLC Unmet Needs [https://www.delveinsight.com/sample-request/c-met-non-small-cell-lung-cancer-cmetnsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

c-MET NSCLC Companies

AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis , and others.

C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intramuscular
* Intratumoral
* Intravenous
* Molecule Type

c-MET NSCLC Products have been categorized under various Molecule types such as

* Gene therapies
* Bispecific antibodies
* Immunotherapies
* Monoclonal antibodies
* Small molecules
* Product Type

Discover the latest advancements in c-MET NSCLC treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ c-MET NSCLC Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/c-met-non-small-cell-lung-cancer-cmetnsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the c-MET NSCLC Pipeline Report

* Coverage- Global
* c-MET NSCLC Companies- AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis , and others.
* C-MET NSCLC Therapies- Glumetinib, Tepotinib, INC280, APL-101 Oral Capsules, MCLA-129, Osimertinib , and others.
* c-MET NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* c-MET NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of c-MET NSCLC Pipeline on our website @ c-MET NSCLC Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/c-met-non-small-cell-lung-cancer-cmetnsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC): Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Collaboration Deals
* Mid Stage Products (Phase II)
* Telisotuzumab: AbbVie
* PLB1001: Beijing Pearl Biotechnology Limited Liability Company
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* JNJ-61186372: Janssen Research & Development, LLC
* Drug profiles in the detailed report.....
* Pre-clinical and Discovery Stage Products
* Drug profiles in the detailed report.....
* Inactive Products
* C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Companies
* C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Products
* C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Unmet Needs
* C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Market Drivers and Barriers
* C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Future Perspectives and Conclusion
* C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Analyst Views
* C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cmet-nsclc-pipeline-outlook-2025-insights-into-therapies-research-and-market-potential]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/c-met-non-small-cell-lung-cancer-cmetnsclc-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.